Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Cyst Fibros. 2019 Oct 5. pii: S1569-1993(19)30890-2. doi: 10.1016/j.jcf.2019.09.006. [Epub ahead of print]

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

Author information

1
Cystic Fibrosis Center, Children's Hospital, University of Cologne, Faculty of Medicine and University Hospital Cologne, Germany. Electronic address: Silke.vanKoningsbruggen@uk-koeln.de.
2
Galapagos NV, Mechelen, Belgium.
3
Cystic Fibrosis Center Munich-West, Munich, Germany.
4
Cystic Fibrosis Division, Department of Pulmonary Medicine, University of Essen, University Duisburg-Essen, Ruhrlandklinik, Germany.
5
Cystic Fibrosis Center, Klinikum Stuttgart, Stuttgart, Germany.
6
Cystic Fibrosis Center, Department of Pulmonary Medicine, University Hospital, Goethe University, Frankfurt, Germany.
7
Cystic Fibrosis Center, Charité - Universitätsmedizin, Berlin, Germany.
8
Children's Hospital of the University of Tübingen, Tübingen, Germany.
9
Galapagos BV, Leiden, The Netherlands.

Abstract

BACKGROUND:

Triple combinations of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators demonstrate enhanced clinical efficacy in CF patients with F508del mutation, compared with modest effects of dual combinations. GLPG2737 was developed as a novel corrector for triple combination therapy.

METHODS:

This multicenter, randomized, double-blind, placebo-controlled, phase 2a study evaluated GLPG2737 in F508del homozygous subjects who had been receiving lumacaftor 400mg/ivacaftor 250mg for ≥12weeks. The primary outcome was change from baseline in sweat chloride concentration. Other outcomes included assessment of pulmonary function, respiratory symptoms, safety, tolerability, and pharmacokinetics.

RESULTS:

Between November 2017 and April 2018, 22 subjects were enrolled and randomized to oral GLPG2737 (75mg; n=14) or placebo (n=8) capsules twice daily for 28days. A significant decrease from baseline in mean sweat chloride concentration occurred at day 28 for GLPG2737 versus placebo (least-squares-mean difference-19.6mmol/L [95% confidence interval (CI) -36.0, -3.2], p=.0210). The absolute improvement, as assessed by least-squares-mean difference in change from baseline, in forced expiratory volume in 1s (percent predicted) at day 28 for GLPG2737 versus placebo was 3.4% (95% CI -0.5, 7.3). Respiratory symptoms in both groups remained stable. Mild/moderate adverse events occurred in 10 (71.4%) and 8 (100%) subjects receiving GLPG2737 and placebo, respectively. Lower exposures of GLPG2737 (and active metabolite M4) were observed than would be expected if administered alone (as lumacaftor induces CYP3A4). Lumacaftor and ivacaftor exposures were as expected.

CONCLUSIONS:

GLPG2737 was well tolerated and yielded significant decreases in sweat chloride concentration versus placebo in subjects homozygous for F508del receiving lumacaftor/ivacaftor, demonstrating evidence of increased CFTR activity when added to a potentiator-corrector combination.

FUNDING:

Galapagos NV.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT03474042.

KEYWORDS:

CFTR corrector; Combination therapy; Efficacy; GLPG2737; Ivacaftor; Lumacaftor

PMID:
31594690
DOI:
10.1016/j.jcf.2019.09.006
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center